Cilostazol Tablet
Product Images NDC 0093-2064

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cilostazol (NDC 0093-2064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure For Cilostazol (Image 1)

Chemical structure diagram of Cilostazol, showing its molecular connections including a cyclohexyl group attached to a triazole ring, connected to a chromone moiety with an oxygen linker.*

FDA Label Image

Figure1 (Image 2)

A line graph depicting plasma concentration (ng/mL) over time (hrs) for Cilostazol and its metabolites 3,4-dehydrocilostazol and 4'-trans-hydroxycilostazol. Cilostazol shows the highest plasma concentration peaking around 2-4 hours, with concentrations gradually decreasing up to 24 hours. The two metabolites have lower plasma concentrations, with 3,4-dehydrocilostazol higher than 4'-trans-hydroxycilostazol throughout the time course.*

FDA Label Image

Figure 2 (Image 3)

A bar graph comparing the percent mean improvement in maximal walking distance among groups receiving placebo, Cilostazol 50 mg twice daily, and Cilostazol 100 mg twice daily across multiple clinical trials. The graph shows higher improvement percentages with Cilostazol doses compared to placebo over different trial durations of 12, 16, and 24 weeks, with varying sample sizes noted for each trial.*

FDA Label Image

Image (Image 4)

Label for Cilostazol Tablets USP 50 mg oral tablets by Teva Pharmaceuticals USA, Inc. The label includes NDC 0093-2065-06, dispensing instructions, usual dosage of one tablet twice daily, storage conditions, and pharmacist dispensing note with patient information leaflet. The package contains 60 tablets.*

FDA Label Image

Image (Image 5)

Cilostazol Tablets USP 100 mg oral tablet label by Teva Pharmaceuticals USA, Inc. The label states an NDC of 0093-2064-06 and indicates a package count of 60 tablets. Instructions note dispensing with an attached patient information leaflet and a usual dosage of one tablet twice daily, with storage between 20°C to 25°C. The label includes regulatory and manufacturing information, a barcode, and the Teva logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.